Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and High-Dose Pemetrexed for Progressive Chordoma
NCT06794645Phase 2Recruiting
- Sponsor
- Providence Saint John's Cancer Institute
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, pemetrexed in chordoma, sponsored by Providence Saint John's Cancer Institute. Started Jan 2025; status: recruiting.
02
Drugs
pembrolizumabpemetrexed
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT06794645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794645.